Literature DB >> 15123089

Photodynamic therapy in cholangiocarcinomas.

Maria-Anna Ortner1.   

Abstract

Symptoms occur late in cholangiocarcinoma and therefore only about half of the patients at the time of diagnosis are candidates for curative surgery. In patients with advanced non-resectable cholangiocarcinoma palliative treatment options are limited. Until now, insertion of endoprostheses for the treatment of cholestasis has been the method of choice. However, tumour growth cannot be influenced and so that prognosis is dismal. Although radiotherapy and chemotherapy are frequently used, prospective, randomized trials showing an improvement in survival time are missing. Encouraging results from prospective, single-arm phase II trials and a randomized trial using photodynamic therapy (PDT) in non-resectable cholangiocarcinoma indicate considerable benefit on survival with a good quality of life. Furthermore, PDT is well tolerated, with only few specific side-effects. This is of great importance in patients with short life expectancy. PDT should therefore be offered to all patients with non-resectable cholangiocarcinoma. However, before initiating PDT or any other palliative measure, a proper staging and a surgical consultation is necessary to avoid missing a curative surgical option.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123089     DOI: 10.1016/S1521-6918(03)00100-8

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  2 in total

Review 1.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

2.  Photodynamic Therapy Using Hippo Pathway Inhibitor Verteporfin: A Potential Dual Mechanistic Approach in Treatment of Soft Tissue Sarcomas.

Authors:  Jeffrey D Rytlewski; Nicholas Scalora; Keith Garcia; Munir Tanas; Fatima Toor; Benjamin Miller; Bryan Allen; Mohammed Milhem; Varun Monga
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.